Percentage of Older Men and Women with age as a significant risk factor and a calculated 10-year hip fracture risk ≥3% who underwent evaluation of osteoporosis and pharmacotherapy to prevent osteoporotic fracture
| Older Men | Older Women | |||||||
| 70–74 years (%) (n=5189) | 75–79 years (%) (n=3004) | ≥80 years (%) (n=3411) | All >70 years (%) (n=11 604) | 70–74 years (%) (n=151) | 75–79 years (%) (n=118) | ≥80 years (%) (n=194) | All >70 years (%) (n=463) | |
| 10-year hip fracture risk ≥3% | 2 | 48 | 88 | 39 | 24 | 89 | 99 | 72 |
| Evaluation | ||||||||
| DXA obtained | 12 | 13 | 10 | 12 | 75 | 67 | 51 | 63 |
| Serum 25-hydroxy vitamin D measured | 22 | 17 | 14 | 18 | 56 | 28 | 32 | 39 |
| Treatment | ||||||||
| Calcium/Vitamin D supplements | 20 | 19 | 18 | 20 | 74 | 64 | 54 | 63 |
| Bisphosphonate prescription (at least once) | 4 | 6 | 7 | 5 | 33 | 52 | 48 | 44 |
All tests for trend were significant at p<0.01 or p=0.01.
DXA, dual-energy X-ray absorptiometry.